GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles

• Status: Unknown status
• Trial end date: 2016-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

In-Vitro Fertilisation (IVF) is the term commonly applied to a form of treatment for infertility that involves controlled ovarian hyperstimulation, egg maturation, egg collection, fertilisation, embryo culture and finally embryo transfer. The period after egg collection is called luteal phase. In Australia, vaginal progesterone is routinely used to support the lining of the uterus so that it is susceptible to implantation of the embryos.

More recently, there has been some suggestion that additional supplementation of luteal phase with GnRH agonist increases clinical pregnancy and live birth rate. These studies are however heterogeneous and results were inconsistent.

This study is a prospective randomised controlled trial of additional GnRH agonist in luteal phase of antagonist cycle. The primary hypothesis is that GnRH agonist increases the number of live birth . The secondary hypothesis is that this increases the clinical pregnancy rate, on-going pregnancy rate, without affecting the miscarriage rate, ovarian hyperstimulation rate and multiple pregnancy rate.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Queensland Fertility Group
• Treatments: Deslorelin; Leuprolide; Progesterone

Criteria

Inclusion Criteria:

1. Single embryo transfer

2. Antagonist cycle with HCG trigger

3. Use of progesterone as luteal phase support (crinone or progesterone pessary )

4. Women undergoing their first IVF cycle with TFC

5. Age 18-42 inclusive

Exclusion Criteria:

No or frozen embryo transfer planned b. Use of other luteal support c. Known contraindication to the use of GnRH analogue